Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.49 |
| ▸ | MET | P08581 | 7/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL543401 | 0.89 | ABL1 (0.58) | ABL1AURKBMETCYP3A4KMT2A | |
| SCHEMBL544180 | 0.85 | ABL1 (0.56) | ABL1AURKBMETCYP3A4KMT2A | |
| SCHEMBL543975 | 0.85 | ABL1 (0.60) | ABL1AURKBMETCYP3A4KMT2A | |
| SCHEMBL543775 | 0.84 | ABL1 (0.53) | ABL1AURKBMETCYP3A4KMT2A | |
| SCHEMBL544820 | 0.84 | ABL1 (0.58) | ABL1AURKBMETCYP3A4KMT2A | |
| SCHEMBL544033 | 0.81 | GHSR (0.52) | ABL1METCYP3A4KMT2AMEN1 | |
| SCHEMBL544405 | 0.81 | ABL1 (0.52) | ABL1AURKBMETCYP3A4KMT2A | |
| SCHEMBL543982 | 0.81 | GHSR (0.51) | ABL1METKMT2AMEN1POLB | |
| SCHEMBL543827 | 0.81 | GHSR (0.51) | ABL1METKMT2AMEN1POLB | |
| SCHEMBL544204 | 0.80 | ABL1 (0.58) | ABL1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110571-B2 | Tyrosine kinase inhibitors; antiproliferation agents; metabolism diseases; antiallergens; central nervous system disorders; vision and skin disorders; antiarthritic agents | AVENTIS PHARMA S.A. (FR) | 2012-02-07 | — | — | US | disclosed |
| US-20080194555-A1 | Novel Benzimidazole and Benzothiazole Derivatives, Method for Preparing Same, Use Thereof as Drugs, Pharmaceutical Compositions and Novel Use Especially as c-MET Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194555-A1 | Novel Benzimidazole and Benzothiazole Derivatives, Method for Preparing Same, Use Thereof as Drugs, Pharmaceutical Compositions and Novel Use Especially as c-MET Inhibitors | MET, KIT, MERTK | ABL1 6/4885AURKB 555/4885MET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.